{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:34:29Z","timestamp":1793190869988,"version":"4.5.0"},"reference-count":27,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:00:00Z","timestamp":1694822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1-TR-000040"],"award-info":[{"award-number":["UL1-TR-000040"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1-RR-024156"],"award-info":[{"award-number":["UL1-RR-024156"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Irving Institute for Clinical and Translational Research\/Clinical Trials Office Pilot Award","award":["DK112093"],"award-info":[{"award-number":["DK112093"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Treatment of hyperprolactinemia with ergoline dopamine agonists (DAs) can be complicated by intolerance and resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study examines the efficacy and tolerability of the nonergot DA ropinirole for the long-term treatment of hyperprolactinemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twelve hyperprolactinemic women were treated with ropinirole in a 6-month, open-label, dose-escalation trial; 7 of the 12 continued treatment in an extension study for up to 17 months. Ropinirole doses were uptitrated to achieve normal prolactin (PRL) levels, restore menses, and eliminate galactorrhea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two of the 12 participants were DA naive; 6 of 12 were ergot DA intolerant; and 1 of 12 had known ergot DA resistance. Baseline PRL levels were 126.2 \u00b1 41.4 ng\/mL (SEM). Ropinirole was uptitrated from 0.125 to 0.25 mg\/h to a median total daily dose (TDD) of 2 mg\/d (1-4 mg\/d [interquartile range]). PRL normalization was achieved in 50% of the participants (5 with microadenomas and 1 with idiopathic hyperprolactinemia) at a median effective TDD of 1 mg\/d. Of the patients achieving PRL normalization, 83% were ergot DA intolerant. A persistent partial biochemical response (PRL reduction &amp;gt;50% from baseline) was achieved in 17% of the participants. During treatment, menses resumed in 67% of amenorrheic patients; galactorrhea resolved in 67%. Mild adverse effects were reported in 92% of participants; however, ropinirole was not discontinued because of intolerance even among the 50% of individuals with a prior history of ergot DA intolerance and resultant medication discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These data demonstrate the efficacy and tolerability of ropinirole for the treatment of hyperprolactinemia in patients with microprolactinomas and idiopathic hyperprolactinemia and suggest ropinirole may represent a novel therapeutic alternative for treating hyperprolactinemic disorders in patients with ergot DA intolerance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgad545","type":"journal-article","created":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T12:56:22Z","timestamp":1694868982000},"page":"e667-e674","source":"Crossref","is-referenced-by-count":4,"title":["Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability"],"prefix":"10.1210","volume":"109","author":[{"given":"Liam J","family":"Heneghan","sequence":"first","affiliation":[{"name":"Department of Medicine, Columbia University, Vagelos College of P&S , New York, NY 10032 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Tsang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University, Vagelos College of P&S , New York, NY 10032 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Dimino","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University, Vagelos College of P&S , New York, NY 10032 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander G","family":"Khandji","sequence":"additional","affiliation":[{"name":"Department of Radiology, Columbia University Irving Medical Center , New York, NY 10032 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K","family":"Panigrahi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University, Vagelos College of P&S , New York, NY 10032 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4064-1211","authenticated-orcid":false,"given":"Gabrielle","family":"Page-Wilson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University, Vagelos College of P&S , New York, NY 10032 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,9,16]]},"reference":[{"issue":"14","key":"2024011817420437100_dgad545-B1","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"issue":"2","key":"2024011817420437100_dgad545-B2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024011817420437100_dgad545-B3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11102-005-5085-2","article-title":"Pharmacologic resistance in prolactinoma patients","volume":"8","author":"Molitch","year":"2005","journal-title":"Pituitary"},{"issue":"7","key":"2024011817420437100_dgad545-B4","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients","volume":"84","author":"Verhelst","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024011817420437100_dgad545-B5","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/bcp.15660","article-title":"Dopamine agonists for the treatment of pituitary tumours: from ergot extracts to next generation therapies","volume":"89","author":"Wexler","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2024011817420437100_dgad545-B6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.102.039867","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes","volume":"303","author":"Millan","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2024011817420437100_dgad545-B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-020-0507-8","article-title":"Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study","volume":"20","author":"Budayr","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"2024011817420437100_dgad545-B8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"2024011817420437100_dgad545-B9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12020-017-1271-z","article-title":"Cabergoline for hyperprolactinemia: getting to the heart of it","volume":"57","author":"Nachtigall","year":"2017","journal-title":"Endocrine"},{"issue":"12","key":"2024011817420437100_dgad545-B10","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1210\/jc.2008-2244","article-title":"The cabergoline-resistant prolactinoma patient: new challenges","volume":"93","author":"Molitch","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"1 Part 2","key":"2024011817420437100_dgad545-B11","first-page":"17S","article-title":"Clinical pharmacology of dopamine agonists","volume":"20","author":"Lam","year":"2000","journal-title":"Pharmacotherapy"},{"issue":"Issue 1, Supplement 1","key":"2024011817420437100_dgad545-B12","first-page":"S58","article-title":"Pharmacologic profile of ropinirole: a nonergoline dopamine agonist","volume":"49","author":"Tulloch","year":"1997","journal-title":"Neurology"},{"issue":"4","key":"2024011817420437100_dgad545-B13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2125.1989.tb03524.x","article-title":"A dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D2-receptor agonist","volume":"28","author":"Acton","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"2024011817420437100_dgad545-B14","first-page":"118","article-title":"Pituitary hormones in Parkinson's disease before and after inititaion of dopamine agonists","volume":"15","author":"Fukushima","year":"2000","journal-title":"Mov Disord"},{"issue":"2","key":"2024011817420437100_dgad545-B15","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bcp.13802","article-title":"Pharmacokinetics and pharmacodynamics of ropinirole in patients with prolactinomas","volume":"85","author":"Liu","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2024011817420437100_dgad545-B16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/eje.0.1480325","article-title":"Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia","volume":"148","author":"Colao","year":"2003","journal-title":"Eur J Endocrinol"},{"issue":"21","key":"2024011817420437100_dgad545-B17","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","article-title":"Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia","volume":"349","author":"Colao","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"2024011817420437100_dgad545-B18","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1210\/jc.2003-030979","article-title":"Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis","volume":"89","author":"Colao","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2024011817420437100_dgad545-B19","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy","volume":"86","author":"Di Sarno","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024011817420437100_dgad545-B20","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-2265.1994.tb02799.x","article-title":"Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine","volume":"41","author":"Vilar","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2024011817420437100_dgad545-B21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/eje.1.02075","article-title":"Quinagolide\u2013a valuable treatment option for hyperprolactinaemia","volume":"154","author":"Barlier","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2024011817420437100_dgad545-B22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/EJE-18-0682","article-title":"Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas","volume":"180","author":"Ioachimescu","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2024011817420437100_dgad545-B23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2265.1990.tb00899.x","article-title":"A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia","volume":"32","author":"Homburg","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2024011817420437100_dgad545-B24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11102-023-01313-8","article-title":"How to manage intolerance to dopamine agonist in patients with prolactinoma","volume":"26","author":"Stumpf","year":"2023","journal-title":"Pituitary"},{"issue":"6","key":"2024011817420437100_dgad545-B25","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s11102-021-01188-7","article-title":"Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis","volume":"24","author":"Yagnik","year":"2021","journal-title":"Pituitary"},{"issue":"6","key":"2024011817420437100_dgad545-B26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1701-2163(16)32866-3","article-title":"Medications for restless legs syndrome in pregnancy","volume":"30","author":"Djokanovic","year":"2008","journal-title":"J Obstet Gynaecol Can"},{"issue":"9","key":"2024011817420437100_dgad545-B27","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/ene.12001","article-title":"Pregnancy outcome following use of levodopa, pramipexole, ropinirole, and rotigotine for restless legs syndrome during pregnancy: a case series","volume":"20","author":"Dostal","year":"2013","journal-title":"Eur J Neurol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad545\/51743192\/dgad545.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/2\/e667\/55529272\/dgad545.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/2\/e667\/55529272\/dgad545.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T12:45:48Z","timestamp":1705581948000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/2\/e667\/7275652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,16]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,9,16]]},"published-print":{"date-parts":[[2024,1,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad545","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,9,16]]}}}